Last reviewed · How we verify
AFFITOPE AD01
At a glance
| Generic name | AFFITOPE AD01 |
|---|---|
| Sponsor | Affiris AG |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- AD01 Follow up Extension Visit
- Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease (PHASE1)
- Long-term Safety and Tolerability of AFFITOPE AD01
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AFFITOPE AD01 CI brief — competitive landscape report
- AFFITOPE AD01 updates RSS · CI watch RSS
- Affiris AG portfolio CI